2,500 years ago in Greece, Hippocrates, the Father of Medicine, said, “All diseases begin in the gut.”

GLP-1 agonist meds like Ozempic reduce food, alcohol and cocaine intake and may improve behavioral addictions.

GLP-1 receptors exist in areas of the brain where drugs and alcohol are believed to cause pleasure.

What began as an unexpected observation and “side effect” of some medications converged with decades of addiction neuroscience: GLP-1 receptor agonist medications like Ozempic apparently reduce alcohol craving, drinking intensity, and relapses.

If you or someone close to you struggles with alcohol use, it may help to know that medication originally developed for diabetes and obesity—semaglutide or other glucagon-like peptide-1 (GLP-1) receptor agonists—may one day become a treatment for alcohol use disorder (AUD). Not only may there be a new pharmacotherapy for AUD, but the success of these drugs forces a reconceptualization of addiction itself. This means AUD is not just a disease of the brain, but the gut may be involved too.

For 40 years, my work and that of others supported the view that addiction is a disorder of maladaptive dopaminergic learning. Our understanding was that drugs of abuse hijacked parts of the brain. The model wasn’t wrong, but was incomplete.

Emerging evidence now shows addiction isn’t exclusively a disorder of synapses and dopamine. Instead, addiction involves many systems, including gut sensory signaling, endocrine modulation, immune tone, microbiome-dependent stress regulation, and central reward circuitry. This has been reinforced by anti-addiction findings for GLP-1s.

GLP-1 Signaling at the Intersection of Metabolism and Reward

The gut and brain communicate via the vagus nerve, so gut health directly impacts mood, anxiety, and neurodegenerative conditions. In addition, gut microbes trigger the release of substances that travel to the brain and influence it. GLP-1 itself is a gut-derived incretin hormone released by the enteroendocrine cells in response to nutrient intake. Its classical functions are slowing gastric emptying, enhancing insulin secretion, and boosting satiety (feeling full). Over the past decade, studies have shown GLP-1 receptor agonists like semaglutide (Ozempic or Wegovy)........

© Psychology Today